Trial Profile

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Docetaxel; Infliximab; Mycophenolate mofetil
Indications Brain metastases; Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms LATIFY
Sponsors AstraZeneca

24 Sep 2025 Planned End Date changed from 8 Sep 2025 to 6 Oct 2025.
24 Sep 2025 Planned primary completion date changed from 8 Sep 2025 to 6 Oct 2025.
15 Aug 2025 Planned End Date changed from 22 Aug 2025 to 8 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com